On the stock market since 1982, it operates in the world of health and science. It has 1,554 employees. Now — the numbers.
This is an established company with proven profits.
No real growth (-1% a year). Red columns mark years that ended in a loss.
If every debt were paid off today, $879.4M would still be left in the vault — a solid cushion for hard times.
Executives buying with their own money is usually read as confidence in the company’s future.
The stock trades 46% below its peak. The market has trimmed its expectations for the company.
There is $879.4M in the vault; even if every debt were paid off, $879.4M would remain.
Over the last 12 months, company executives reported 19 buys and 5 sells. Management buying with its own money is usually read as a good sign.
Nothing in the current numbers stands out as a clear risk. Still, no stock is ever risk-free.
On our five-subject report card, TARO sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: TARO is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.